Press release
Bronchopulmonary Dysplasia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more about our innovative pipeline today! @ Bronchopulmonary Dysplasia Pipeline Outlook [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
* On 27 August 2025, OHB Neonatology Ltd. announced a study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
* DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
* The leading Bronchopulmonary Dysplasia Companies such as Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Promising Bronchopulmonary Dysplasia Pipeline Therapies such as Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
Download for updates and be a part of the revolution in Respiratory Diseases Care @ Bronchopulmonary Dysplasia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Emerging Drugs Profile
* AT-100: Airway Therapeutics, Inc
Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of the human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. This therapeutic candidate primarily targets bronchopulmonary dysplasia (BPD). Currently, the drug is in the Phase III stage of its development for the treatment of Bronchopulmonary dysplasia.
* OHB-607: Oak Hill Bio
OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio, aimed at addressing significant health challenges faced by extremely premature infants. This investigational drug is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. It is specifically designed to prevent bronchopulmonary dysplasia (BPD). OHB-607 aims to restore IGF-1 levels to those typically present in full-term pregnancies, thereby supporting the normal growth and development of vital organs like the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of its development for the treatment of Bronchopulmonary dysplasia.
The Bronchopulmonary Dysplasia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
* Bronchopulmonary Dysplasia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities in our groundbreaking Bronchopulmonary Dysplasia research and development projects @ Bronchopulmonary Dysplasia Unmet Needs [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bronchopulmonary Dysplasia Companies
Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay informed about how we're transforming the future of Respiratory Disease @ Bronchopulmonary Dysplasia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bronchopulmonary Dysplasia Pipeline Report
* Coverage- Global
* Bronchopulmonary Dysplasia Companies- Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics Inc . and others.
* Bronchopulmonary Dysplasia Pipeline Therapies- Zelpultide alfa, Inhaled Nitric Oxide, Sildenafil, Pneumostem Registered , Curosurf, OHB-607, Infasurf, Palivizumab and others.
* Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ Bronchopulmonary Dysplasia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bronchopulmonary Dysplasia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchopulmonary Dysplasia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AT-100: Airway Therapeutics, Inc
* Mid Stage Products (Phase II)
* OHB-607: Oak Hill Bio
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Bronchopulmonary Dysplasia Key Companies
* Bronchopulmonary Dysplasia Key Products
* Bronchopulmonary Dysplasia- Unmet Needs
* Bronchopulmonary Dysplasia- Market Drivers and Barriers
* Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
* Bronchopulmonary Dysplasia Analyst Views
* Bronchopulmonary Dysplasia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4167117 • Views: …
More Releases from ABNewswire
Ultrasound Devices Market Set for Sustained Expansion, Driven by Technological I …
The global ultrasound devices market is growing at a CAGR of 4.38% during the forecast period from 2025 to 2032.
The global ultrasound devices market, estimated at USD 6.76 billion in 2023, is anticipated to grow at a CAGR of 6.82% from 2024 to 2030, reaching approximately USD 10.05 billion by the end of the forecast period. The market's upward trajectory is attributed to the growing incidence of chronic diseases such…
SAYYAS was awarded the title of National 5G Factory
Recently, the Ministry of Industry and Information Technology released the "2025 5G Factory List". By virtue of systematic innovation and practice in the field of "5G+Industrial Internet", SAYYAS has successfully been selected as a national 5G factory, becoming one of the first enterprises in Heilongjiang Province to win this honor.
As a leading brand in the Door And Window [https://www.sayyas.net/door-and-window/] industry, SAYYAS has actively promoted the transformation of intelligent manufacturing in…
Broches and Badges: The Modern Renaissance of Fashion Accessories
Brooches and badges have experienced a stunning renaissance in recent years, transforming from traditional ornaments into vibrant symbols of personal expression. Once relegated to the realm of vintage [https://www.jinjieaccessory.com/vintage/] fashion, these accessories are now making bold appearances on the runways and in everyday wardrobes.
Image: https://ecdn6.globalso.com/upload/p/2299/image_product/2024-10/news003.jpg
The renewed interest in brooches and badges can be attributed to the growing desire for stylish individuality. As consumers increasingly seek to stand out from the…
T&K Asphalt Promotes Chris Duffy to President
WHITMAN, MA - October 30, 2025 - T&K Asphalt Services, Inc. [https://www.tkasphalt.com/], New England's largest commercial parking lot maintenance company [https://www.tkasphalt.com/commercial/], today announced the promotion of Chris Duffy to the role of President. In his new capacity, Chris will oversee the company's daily operations, leveraging his extensive industry knowledge and leadership skills to drive growth and maintain the high-quality service T&K customers expect.
Steve Rose will transition to the role of…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
Bronchopulmonary Dysplasia Market to Reach US$ 445.6 Million by 2034
Market Overview:
The bronchopulmonary dysplasia market reached a value of US$ 269.3 Million in 2023 and expected to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The report offers a comprehensive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,…
